REFERENCES
- SC Sweetman. Martindale: The Complete Drug Reference, 33 ed. London: Pharmaceutical Press: London; 921.
- J Carini, and JV Duncia. Angiotensin II receptor blocking imidazoles. European Patent Application 0253310, Issued to E. I. DuPont de Nemours & Co., Inc. Wilmington DE, (1988).
- JV Duncia, AT Chiu, DJ Carini, and et al (1990). J. Med. Chem. 33:1312.
- MW La, PS Wissel, OB Bialy, and et al (1992). Hypertens. 10:5133.
- MW Lo, H Lu, DM Farrell, and et al (1992). Pharmaceut. Res. 9:5308.
- PC Wong, WA PriceJr., AT Chiu, and et al (1990). J. Pharmacol. Exp. Ther 255:211.
- CS Sweet, and EB Nelson. (1993). J. Hypertens. 11:63.
- RA Steams, RR Miller, GA Doss, and et al (1992). Drug Metab. Dispos. 20:281.
- BL Carter, ME Ernst, and JD Cohen. (2004). Hypertension 43:4.
- MR Balesteros, AF Faria, and ALO Marcone. (2007). J. Braz. Chem. Soc. 18:554.
- JC Roos, P Boer, HA Koomans, GG Geyskens, and EJ Dorhout Mees. (1981). Eur. J. Clin. Pharmacol. 19:107.
- M Moser. (1998). JAMA. 279:1813.
- P Larochelle, and AG Logan. (1985). Can. Med. Assoc. J. 132:801.
- MK Pandit, BJ Gustafson, AB Minocha, and AN Peiris. (1993). Ann. Int. Med. 118:529.
- AP Niarchaos, DL Weinstein, and JH Laragh. (1984). Am. J. Med. 77:1061.
- Y Lacourciere, and L Poirier. (2003). Am. J. Hypertension 16:1036.
- TZ Dickson, JA Zagrobelny, CL Charles, and et al (2003). J. Clin. Pharmacol. 43:591.
- CI Furtek, and M-W Lo. (1992). J Chromatogr Biomed. 573:295–301.
- H Lee, HO Shim, and HS Lee. (1996). Chromatographia. 42:39–42.
- B-S Kuo, A Mandagere, DR Osborne, and K-K Hwang. (1990). Pharm Res. 7:1257–1261.
- I Niopas, and AC Daftsios. (2002). J Liq Chromatogr R T. 25:487–494.
- A Soldner, H Spahn-Langguth, and E Mutschler. (1998). J Pharm Biomed Anal. 16:863–873.
- D Zendelovska, T Stafilov, and P Miloševski. (2004). Biomed Chromatogr. 18:71–76.
- JX De Vries, and A Voss. (1993). Biomed Chromatogr. 7:12–14.
- RB Miller, and C Amestoy. (1992). J Pharm Biomed Anal. 10:541–545.
- CT Azumaya. (1990). J Chromatogr B. 532:168–174.
- PKF Yeung, A Jamieson, GJ Smith, D Fice, and PT Pollak. (2000). Int. J Pharm. 204:17–22.
- A Zarghi, SM Foroutan, A Shafaati, and A Khoddam. (2005). Arzneim.Forsch. 55:569–572.
- A Medvedovici, C Mircioiu, and DS Miron. (2000). Eur J Drug. Metab Ph. 25:91–96.
- D Farthing, D Sica, I Fakhry, A Pedro, and TWB Gehr. (1997). J. Chromatogr B. 704:374–378.
- JJI Tamimi, II Salem, SM Alam, Q Zaman, and R Dham. (2005). Biopharm Drug Dispos. 26:205–210.
- MA Ritter, CI Furtek, and M-W Lo. (1997). J Pharm Biomed Anal. 15:1021–1029.
- K Richter, R Oertel, and W Kirch. (1996). J Chromatogr A. 729:293–296.
- T Iwasa, T Takano, K-I Hara, and T Kamei. (1999). J Chromatogr B. 734:325–330.
- M Polinko, K Riffel, H Song, and M-W Lo. (2003). J Pharm Biomed Anal. 33:73–84.
- R Koytchev, Y Ozalp, A Erenmemisoglu, MJ Van der Meer, and RS Alban. (2004). Arzneim Forsch. 54:611–617.
- JD Franolic, GJ Lehr, TL Barry, and G Petzinger. (2001). J Pharm Biomed Anal. 26:651–663.
- T Takubo, H Okada, M Ishii, K-I Hara, and Y Ishii. (2004). J Chromatogr B. 806:199–203.
- NVS Ramakrishna, KN Vishwottam, S Manoj, M Koteshwara, S Wishu, and DP Varma. (2005). Biomed Chromatogr. 19:751–760.
- F Kolocouri, Y Dotsikas, and C Apostolou. (2007). Anal Bioanal Chem. 387:593–601.
- TZ Dickson, and et al (2003). J. Clin. Pharmacol. 43:591–603.
- Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products–General Considerations, 2003. Available at www.fda.gov/cder/guidance/5356fnl, Accessed February 22, 2007.
- Method Validation for Extemporaneous Pediatric Formulation Prototypes of Quinapril Hydrochloride / Assay and Stability Method. Pfizer Global Research and Development, Ann Arbor, Michigan, (November 2001).
- Validation of Analytical Procedures: Methodology, ICH-Q2B, International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, (1996).
- Guidance for Industry: Analytical Procedures and Method Validation, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, Maryland, (2000).
- Validation of Analytical Methods for Drug Products, Pfizer Global Research and Development, Ann Arbor, Michigan, (2001).
- DJ Schuirmann. (1987). J Pharmacokinet. Biopharm. 15:657.
- CS Chow, and J P Liu. Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel Dekker; (1992).
- RA Stearns, PK Chakravarty, and R Chen. (1995). Drug Metabolism and Disposition. 23:207.
- M Ohtawa, F Takayama, K Saitoh, T Yoshinaga, and M Nakashima. (1993). Br. J. Clin. Pharmac. 35:290–297.